|
EP3050963B1
(en)
|
2005-03-31 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Process for production of polypeptide by regulation of assembly
|
|
US9670269B2
(en)
|
2006-03-31 |
2017-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of modifying antibodies for purification of bispecific antibodies
|
|
ES2892925T3
(es)
|
2006-03-31 |
2022-02-07 |
Chugai Pharmaceutical Co Ltd |
Métodos para controlar la farmacocinética en sangre de anticuerpos
|
|
CN101874042B9
(zh)
|
2007-09-26 |
2019-01-01 |
中外制药株式会社 |
利用cdr的氨基酸取代来改变抗体等电点的方法
|
|
AU2008304748C1
(en)
|
2007-09-26 |
2014-06-12 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant region
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
JP5889181B2
(ja)
|
2010-03-04 |
2016-03-22 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
EP3029066B1
(en)
|
2010-07-29 |
2019-02-20 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
PH12016502073B1
(en)
|
2010-11-17 |
2024-04-05 |
Chugai Pharmaceutical Co Ltd |
Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
|
|
RS67768B1
(sr)
|
2010-11-30 |
2026-03-31 |
Chugai Pharmaceutical Co Ltd |
Terapijski agens koji indukuje citotoksičnost
|
|
US9683052B2
(en)
*
|
2011-03-25 |
2017-06-20 |
Glenmark Pharmaceuticals S.A. |
Hetero-dimeric immunoglobulins
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
EP2892924B1
(en)
*
|
2012-06-14 |
2020-11-25 |
Therapix Biosciences Ltd. |
Humanized antibodies to cluster of differentiation 3 (cd3)
|
|
CA2886036A1
(en)
*
|
2012-09-25 |
2014-04-03 |
Ichnos Sciences SA |
Purification of hetero-dimeric immunoglobulins
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
CA2898100C
(en)
|
2013-01-14 |
2023-10-10 |
Xencor, Inc. |
Novel heterodimeric proteins
|
|
US9738722B2
(en)
|
2013-01-15 |
2017-08-22 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
CN105283201B
(zh)
|
2013-03-14 |
2019-08-02 |
斯克利普斯研究所 |
靶向剂抗体偶联物及其用途
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
EP2970486B1
(en)
|
2013-03-15 |
2018-05-16 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
JP6534615B2
(ja)
|
2013-09-27 |
2019-06-26 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
|
CN110627907B
(zh)
*
|
2013-11-04 |
2024-03-29 |
艾科诺斯科技股份有限公司 |
重靶向t细胞的异源二聚免疫球蛋白的产生
|
|
UA129760C2
(uk)
|
2013-12-17 |
2025-07-30 |
Дженентек, Інк. |
Анти-cd3 антитіло та спосіб його застосування
|
|
JP6775422B2
(ja)
|
2014-03-28 |
2020-10-28 |
ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． |
Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
|
|
CN118440206A
(zh)
|
2014-04-07 |
2024-08-06 |
中外制药株式会社 |
免疫活化抗原结合分子
|
|
EP3144388B1
(en)
*
|
2014-05-13 |
2020-07-01 |
Chugai Seiyaku Kabushiki Kaisha |
T cell-redirecting antigen-binding molecule for cells having immunosuppression function
|
|
KR20170066421A
(ko)
|
2014-09-12 |
2017-06-14 |
제넨테크, 인크. |
항-cll-1 항체 및 면역접합체
|
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
|
MA40894A
(fr)
*
|
2014-11-04 |
2017-09-12 |
Glenmark Pharmaceuticals Sa |
Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
|
|
BR112017011166A2
(pt)
|
2014-11-26 |
2018-02-27 |
Xencor, Inc. |
anticorpos heterodiméricos que se ligam a cd3 e cd38
|
|
CN110894240B
(zh)
|
2014-11-26 |
2022-04-15 |
森科股份有限公司 |
结合cd3和肿瘤抗原的异二聚体抗体
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
|
JP7237449B2
(ja)
*
|
2015-02-27 |
2023-03-13 |
アイセル・ジーン・セラピューティクス・エルエルシー |
血液系腫瘍を標的としたキメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
|
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
JP7082484B2
(ja)
|
2015-04-01 |
2022-06-08 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
|
GB201506868D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method for protein purification
|
|
CA2984794A1
(en)
|
2015-05-07 |
2016-11-10 |
Agenus Inc. |
Anti-ox40 antibodies and methods of use thereof
|
|
TWI731861B
(zh)
|
2015-06-16 |
2021-07-01 |
美商建南德克公司 |
FcRH5之人源化及親和力成熟抗體及使用方法
|
|
EP3916018A1
(en)
|
2015-06-16 |
2021-12-01 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
EP3310378B1
(en)
|
2015-06-16 |
2024-01-24 |
F. Hoffmann-La Roche AG |
Anti-cll-1 antibodies and methods of use
|
|
MX391086B
(es)
|
2015-06-24 |
2025-03-21 |
Hoffmann La Roche |
Anticuerpos anti-receptor de transferrina con afinidad diseñada.
|
|
TWI833684B
(zh)
|
2015-06-25 |
2024-03-01 |
美商生物細胞基因治療有限公司 |
嵌合抗原受體（ｃａｒ）、組合物及其使用方法
|
|
US11173179B2
(en)
|
2015-06-25 |
2021-11-16 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
NZ741067A
(en)
|
2015-10-02 |
2023-07-28 |
Hoffmann La Roche |
Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
|
|
HRP20211528T1
(hr)
|
2015-10-25 |
2021-12-24 |
Sanofi |
Trispecifični i/ili trovalentni vezujući proteini za prevenciju ili liječenje hiv infekcije
|
|
WO2017086419A1
(ja)
*
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
|
US11660340B2
(en)
|
2015-11-18 |
2023-05-30 |
Chugai Seiyaku Kabushiki Kaisha |
Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
|
|
IL299072A
(en)
|
2015-12-02 |
2023-02-01 |
Memorial Sloan Kettering Cancer Center |
Antibodies and methods for using them
|
|
JP7058219B2
(ja)
|
2015-12-07 |
2022-04-21 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体
|
|
CN110698560B
(zh)
*
|
2015-12-24 |
2021-11-26 |
凯惠科技发展(上海)有限公司 |
一种tpbg抗体及其制备方法、其偶联物和应用
|
|
CN108368166B
(zh)
*
|
2015-12-28 |
2023-03-28 |
中外制药株式会社 |
提高含fc区多肽纯化效率的方法
|
|
AU2017213886B2
(en)
|
2016-02-04 |
2024-03-07 |
The California Institute For Biomedical Research |
Humanized anti-CD3 antibodies, conjugates and uses thereof
|
|
CN109476741B
(zh)
|
2016-03-25 |
2023-02-24 |
拜奥穆尼克斯制药 |
与cd38和pd-l1结合的分子
|
|
IL262241B2
(en)
|
2016-04-13 |
2024-05-01 |
Sanofi Sa |
Trispecific and/or trivalent binding proteins with a crossover dual variable domain arm and a traditional antibody fab arm, pharmaceutical composition comprising said binding proteins and their uses in preventing and/or treating cancer or inflammatory diseases
|
|
HRP20231188T1
(hr)
|
2016-04-13 |
2024-02-02 |
Sanofi |
Trispecifični i/ili trovalentni vezujući proteini
|
|
MA44780A
(fr)
|
2016-04-28 |
2019-03-06 |
Chugai Pharmaceutical Co Ltd |
Préparation contenant un anticorps
|
|
CN109563166B
(zh)
|
2016-04-28 |
2022-12-20 |
拜奥穆尼克斯制药 |
靶向egfr和her2的双特异性抗体
|
|
SI3468586T1
(sl)
|
2016-06-14 |
2025-01-31 |
Xencor, Inc. |
Bispecifična protitelesa za zaviralce kontrolnih točk
|
|
CA3029209A1
(en)
|
2016-06-21 |
2017-12-28 |
Teneobio, Inc. |
Cd3 binding antibodies
|
|
JP7114490B2
(ja)
|
2016-06-24 |
2022-08-08 |
アイセル・ジーン・セラピューティクス・エルエルシー |
キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
|
|
WO2018005706A1
(en)
|
2016-06-28 |
2018-01-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
|
CA3218290A1
(en)
*
|
2016-07-22 |
2018-01-25 |
Amgen Inc. |
Methods of purifying fc-containing proteins
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
FI4050034T3
(fi)
|
2016-09-14 |
2024-06-10 |
Teneoone Inc |
Cd3:een sitoutuvia vasta-aineita
|
|
BR112019005895A2
(pt)
|
2016-09-23 |
2019-06-11 |
Merus N.V. |
moléculas de ligação que modulam uma atividade biológica expressa por uma célula
|
|
CN106632681B
(zh)
|
2016-10-11 |
2017-11-14 |
北京东方百泰生物科技有限公司 |
抗egfr和抗cd3双特异抗体及其应用
|
|
CN110214147A
(zh)
|
2016-10-14 |
2019-09-06 |
Xencor股份有限公司 |
IL15/IL15Rα异源二聚体FC-融合蛋白
|
|
MA46770A
(fr)
|
2016-11-09 |
2019-09-18 |
Agenus Inc |
Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
|
|
WO2018093821A1
(en)
|
2016-11-15 |
2018-05-24 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
NZ754713A
(en)
|
2016-12-21 |
2025-11-28 |
Teneobio Inc |
Anti-bcma heavy chain-only antibodies
|
|
CN106749678A
(zh)
*
|
2017-01-09 |
2017-05-31 |
北京普瑞金科技有限公司 |
Her2 car重组慢病毒载体及其构建方法与应用
|
|
CN120842423A
(zh)
|
2017-03-27 |
2025-10-28 |
拜奥穆尼克斯制药 |
稳定的多特异性抗体
|
|
CN110461358A
(zh)
|
2017-03-31 |
2019-11-15 |
公立大学法人奈良县立医科大学 |
可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
|
|
SG10201912545PA
(en)
*
|
2017-04-24 |
2020-02-27 |
Ichnos Sciences SA |
T cell redirecting bispecific antibodies for the treatment of egfr positive cancers
|
|
EP3409322A1
(en)
|
2017-06-01 |
2018-12-05 |
F. Hoffmann-La Roche AG |
Treatment method
|
|
WO2018224441A1
(en)
*
|
2017-06-05 |
2018-12-13 |
Numab Innovation Ag |
Novel anti-cd3 antibodies
|
|
US11149094B2
(en)
*
|
2017-06-05 |
2021-10-19 |
Janssen Biotech, Inc. |
Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations
|
|
JP7247110B2
(ja)
*
|
2017-06-05 |
2023-03-28 |
ヌマブ セラピューティクス アクチェンゲゼルシャフト |
新規抗ｃｄ３抗体
|
|
IL271194B2
(en)
|
2017-06-20 |
2024-10-01 |
Teneobio Inc |
Anti-bcma heavy chain-only antibodies
|
|
US11427642B2
(en)
|
2017-06-20 |
2022-08-30 |
Teneoone, Inc. |
Anti-BCMA heavy chain-only antibodies
|
|
CA3287539A1
(en)
|
2017-06-21 |
2026-03-02 |
Icell Gene Therapeutics Llc |
CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
|
|
US11084863B2
(en)
|
2017-06-30 |
2021-08-10 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
|
|
US11472880B2
(en)
|
2017-08-14 |
2022-10-18 |
Morphosys Ag |
Humanized antibodies for CD3
|
|
KR20200044094A
(ko)
*
|
2017-09-13 |
2020-04-28 |
테네오바이오, 인코포레이티드 |
엑토효소에 결합하는 중쇄 항체
|
|
CA3078800A1
(en)
|
2017-10-10 |
2019-04-18 |
Sanofi |
Anti-cd38 antibodies and methods of use
|
|
AU2018361430B2
(en)
|
2017-11-01 |
2025-08-14 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody variant and isoform with lowered biological activity
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
KR102782136B1
(ko)
|
2017-11-08 |
2025-03-18 |
쿄와 기린 가부시키가이샤 |
CD40과 EpCAM에 결합하는 이중특이적 항체
|
|
JP2021502100A
(ja)
|
2017-11-08 |
2021-01-28 |
ゼンコア インコーポレイテッド |
新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
|
|
US11319355B2
(en)
|
2017-12-19 |
2022-05-03 |
Xencor, Inc. |
Engineered IL-2 Fc fusion proteins
|
|
RU2020124623A
(ru)
*
|
2017-12-27 |
2022-01-27 |
Тенеобио, Инк. |
Антитела, специфичные к гетеродимеру cd3-дельта/эпсилон
|
|
EP3740505A1
(en)
*
|
2018-01-16 |
2020-11-25 |
Lakepharma Inc. |
Bispecific antibody that binds cd3 and another target
|
|
JP7475275B2
(ja)
|
2018-02-08 |
2024-04-26 |
ジェネンテック， インコーポレイテッド |
二重特異性抗原結合分子及びその使用方法
|
|
US11203646B2
(en)
|
2018-03-14 |
2021-12-21 |
Novimmune Sa |
Anti-CD3 epsilon antibodies and methods of use thereof
|
|
CN110305217B
(zh)
|
2018-03-27 |
2022-03-29 |
广州爱思迈生物医药科技有限公司 |
双特异性抗体及其应用
|
|
WO2019195623A2
(en)
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
US11505595B2
(en)
|
2018-04-18 |
2022-11-22 |
Xencor, Inc. |
TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
|
|
SG11202010163QA
(en)
|
2018-04-18 |
2020-11-27 |
Xencor Inc |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
SI3797121T1
(sl)
*
|
2018-05-23 |
2024-09-30 |
Pfizer Inc. |
Protitelesa, specifična za CD3, in njihova uporaba
|
|
WO2019224385A2
(en)
*
|
2018-05-24 |
2019-11-28 |
Glenmark Pharmaceuticals S.A. |
Combined bispecific antibody and immuno-oncology therapies
|
|
TW202016144A
(zh)
|
2018-06-21 |
2020-05-01 |
日商第一三共股份有限公司 |
包括cd3抗原結合片段之組成物及其用途
|
|
MX2021001915A
(es)
|
2018-08-17 |
2021-05-31 |
Regeneron Pharma |
Metodo y sistema de cromatografia para determinar la cantidad y pureza de una proteina multimerica.
|
|
EP3620785A1
(en)
*
|
2018-09-07 |
2020-03-11 |
Ares Trading S.A. |
Electrophoresis-based characterization of fc fusion proteins
|
|
AU2019348606A1
(en)
*
|
2018-09-25 |
2021-04-15 |
Ichnos Sciences S.A. |
Antibody quantification in biological samples
|
|
EP3861016A2
(en)
|
2018-10-03 |
2021-08-11 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
|
CA3115679A1
(en)
|
2018-10-09 |
2020-04-16 |
Sanofi |
Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection
|
|
BR112021000173A2
(pt)
*
|
2018-10-26 |
2021-05-04 |
Teneobio, Inc. |
anticorpos de cadeia pesada com ligação a cd38
|
|
WO2020112970A1
(en)
*
|
2018-11-30 |
2020-06-04 |
The Trustees Of The University Of Pennsylvania |
Bw6 specific car designed to protect transplanted tissue from rejection
|
|
WO2020132574A1
(en)
|
2018-12-21 |
2020-06-25 |
CentryMed Pharmaceutical Inc. |
Protease cleavable bispecific antibodies and uses thereof
|
|
UA128825C2
(uk)
|
2019-03-01 |
2024-10-30 |
Ксенкор, Інк. |
Гетеродимерні антитіла, що зв'язують enpp3 та cd3
|
|
TW202100556A
(zh)
|
2019-03-14 |
2021-01-01 |
美商建南德克公司 |
使用her2 t細胞依賴性雙特異性抗體之治療
|
|
EP3938405A4
(en)
*
|
2019-03-20 |
2022-12-28 |
Javelin Oncology, Inc. |
ANTI-ADAM12 ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS, AND COMPOSITIONS AND METHODS THEREOF
|
|
JP7776987B2
(ja)
|
2019-04-05 |
2025-11-27 |
テネオバイオ， インコーポレイテッド |
Ｐｓｍａに結合する重鎖抗体
|
|
KR102239781B1
(ko)
|
2019-04-08 |
2021-04-13 |
주식회사 녹십자 |
Gpnmb 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
|
|
US11613576B2
(en)
|
2019-04-09 |
2023-03-28 |
Sanofi |
Trispecific binding proteins, methods, and uses thereof
|
|
IL322315A
(en)
|
2019-05-14 |
2025-09-01 |
Provention Bio Inc |
Methods and preparations for preventing type 1 diabetes
|
|
CN113874399B
(zh)
*
|
2019-05-23 |
2025-07-11 |
维洛斯生物股份有限公司 |
抗ror1/抗cd3双特异性结合分子
|
|
CN114206927B
(zh)
|
2019-06-14 |
2025-03-21 |
特尼奥生物股份有限公司 |
与cd22和cd3结合的多特异性重链抗体
|
|
CN114555633A
(zh)
*
|
2019-06-26 |
2022-05-27 |
约翰霍普金斯大学 |
用于靶向扩增免疫效应细胞的方法和材料
|
|
CN110551221B
(zh)
*
|
2019-07-02 |
2021-03-05 |
广州爱思迈生物医药科技有限公司 |
一种双特异性抗体及其制备方法与应用
|
|
CN114096275B
(zh)
*
|
2019-07-12 |
2025-02-21 |
利普姆股份制有限公司 |
新型bssl抗体
|
|
EP3791931A1
(en)
*
|
2019-09-13 |
2021-03-17 |
Ichnos Sciences SA |
Bispecific antibodies for the treatment of solid tumors
|
|
KR20220071263A
(ko)
|
2019-09-30 |
2022-05-31 |
하버 바이오메드 (쑤저우) 컴퍼니 리미티드 |
Cd3을 표적으로 하는 항체, 이중 특이성 항체 및 이의 용도
|
|
CN112876563B
(zh)
*
|
2019-11-29 |
2022-08-16 |
康诺亚生物医药科技（成都）有限公司 |
药物组合物及其制备方法和应用
|
|
WO2021130717A1
(ko)
*
|
2019-12-26 |
2021-07-01 |
에이비엘바이오 주식회사 |
단백질 a 친화성 크로마토그래피를 이용한 생리활성 펩티드의 정제 방법
|
|
US20230049732A1
(en)
*
|
2019-12-30 |
2023-02-16 |
University Of Louisville Research Foundation, Inc. |
Virus-like particle binding agents, related compositions, and related methods
|
|
WO2021148006A1
(en)
*
|
2020-01-23 |
2021-07-29 |
Adagene Ag |
Heterodimeric proteins with fc mutations
|
|
TWI888487B
(zh)
|
2020-02-14 |
2025-07-01 |
日商協和麒麟股份有限公司 |
與ｃｄ３結合之雙特異性抗體
|
|
EP4106880A4
(en)
*
|
2020-02-17 |
2024-07-03 |
Board of Regents, The University of Texas System |
HUMAN 4-1BB AGONIST ANTIBODIES AND METHODS OF USE THEREOF
|
|
TWI874613B
(zh)
*
|
2020-03-17 |
2025-03-01 |
美商西雅圖免疫公司 |
微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
|
|
JP2024518539A
(ja)
|
2020-04-04 |
2024-05-01 |
ジャナックス セラピューティクス，インク． |
抗体を標的とする腫瘍によって活性化されるｅｇｆｒおよびエフェクター細胞抗原に関する組成物および方法
|
|
WO2021222595A2
(en)
*
|
2020-04-30 |
2021-11-04 |
Virtuoso Binco, Inc. |
Multispecific antibodies targeting cd38 and epcam and uses thereof
|
|
CN116096754A
(zh)
|
2020-05-04 |
2023-05-09 |
免疫里森公司 |
前体三特异性抗体构建体及其使用方法
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
AU2021287998B2
(en)
|
2020-06-11 |
2026-03-12 |
Benaroya Research Institute At Virginia Mason |
Methods and compositions for preventing type 1 diabetes
|
|
AU2021288637A1
(en)
*
|
2020-06-12 |
2023-01-19 |
Ichnos Sciences SA |
Antibody formulation diluent
|
|
US20230322953A1
(en)
*
|
2020-06-30 |
2023-10-12 |
Harbour Biomed (Shanghai) Co., Ltd |
Binding protein having h2l2 and hcab structures
|
|
JP7789304B2
(ja)
*
|
2020-07-31 |
2025-12-22 |
バイオ－テラ ソリュ－ションズ，エルティーディー． |
Ｃｄ４７抗体及びその応用
|
|
US11124568B1
(en)
*
|
2020-08-19 |
2021-09-21 |
Vitruviae LLC |
CD3/CD25 antibodies for neuro-immune diseases
|
|
CA3192204A1
(en)
|
2020-08-19 |
2022-02-24 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
|
US11197910B1
(en)
|
2020-08-19 |
2021-12-14 |
Vitruviae LLC |
Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases
|
|
US12195524B2
(en)
|
2020-08-25 |
2025-01-14 |
Gilead Sciences, Inc. |
Multi-specific antigen binding molecules targeting HIV and methods of use
|
|
WO2022087211A1
(en)
*
|
2020-10-22 |
2022-04-28 |
Janux Therapeutics, Inc. |
Antibodies targeting her2 and cd3 and uses thereof
|
|
CA3196539A1
(en)
|
2020-11-04 |
2022-05-12 |
Chi-Chung Li |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
AU2021374594B2
(en)
|
2020-11-04 |
2026-03-05 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
|
KR20230100732A
(ko)
|
2020-11-04 |
2023-07-05 |
제넨테크, 인크. |
항-cd20/항-cd3 이중특이성 항체의 피하 투여
|
|
WO2022148736A1
(en)
*
|
2021-01-05 |
2022-07-14 |
Transgene |
Vectorization of muc1 t cell engager
|
|
FI4284512T3
(fi)
|
2021-01-28 |
2025-05-22 |
Regeneron Pharma |
Koostumuksia ja menetelmiä sytokiinien vapautumisoireyhtymän hoitamiseksi
|
|
JP2024511319A
(ja)
|
2021-03-09 |
2024-03-13 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
|
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
|
|
TW202304988A
(zh)
*
|
2021-03-24 |
2023-02-01 |
美商健生生物科技公司 |
靶向ＣＤ７９ｂ、ＣＤ２０、及ＣＤ３之三特異性抗體
|
|
CN114763387B
(zh)
*
|
2021-04-15 |
2024-06-25 |
北京大学深圳研究生院 |
一种基于结构优化蛋白活性的三特异性抗体制备方法
|
|
US12291575B2
(en)
|
2021-05-14 |
2025-05-06 |
Genentech, Inc. |
Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
|
|
US12565529B2
(en)
|
2021-05-24 |
2026-03-03 |
Provention Bio, Inc. |
Methods for treating type 1 diabetes
|
|
CN118043357A
(zh)
*
|
2021-08-04 |
2024-05-14 |
阿布普罗公司 |
Cd3靶向抗体及其用途
|
|
US20250019455A1
(en)
*
|
2021-09-24 |
2025-01-16 |
Pharmaceutica Nv |
Proteins comprising cd20 binding domains, and uses thereof
|
|
EP4434548A1
(en)
|
2021-11-15 |
2024-09-25 |
Systimmune, Inc. |
Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof
|
|
US20250092135A1
(en)
*
|
2022-01-10 |
2025-03-20 |
Nanjing Leads Biolabs Co., Ltd. |
Antibody and use thereof
|
|
CN119546329A
(zh)
|
2022-04-11 |
2025-02-28 |
瑞泽恩制药公司 |
用于通用肿瘤细胞杀伤的组合物和方法
|
|
KR20250035053A
(ko)
|
2022-06-07 |
2025-03-11 |
리제너론 파아마슈티컬스, 인크. |
T 세포 활성을 조절하기 위한 다중특이적 분자 및 이의 용도
|
|
WO2024071008A1
(ja)
*
|
2022-09-26 |
2024-04-04 |
愛知県 |
抗原分子の単離方法
|
|
WO2024088987A1
(en)
|
2022-10-26 |
2024-05-02 |
F. Hoffmann-La Roche Ag |
Combination therapy for the treatment of cancer
|
|
JP2025541438A
(ja)
*
|
2022-12-19 |
2025-12-18 |
ハーバー・バイオメド・（シャンハイ）・カンパニー・リミテッド |
「κ／λ」Ｆａｂ－Ｆａｂタンデム型多重特異性結合タンパク質及びその製造と応用
|
|
KR20250151441A
(ko)
|
2023-02-17 |
2025-10-21 |
리제너론 파마슈티칼스 인코포레이티드 |
Cd3/taa 이중특이적 항체에 대해 반응성인 유도된 nk 세포
|
|
WO2025085781A1
(en)
|
2023-10-19 |
2025-04-24 |
Genentech, Inc. |
Combinations of il15/il15r alpha heterodimeric fc-fusion proteins and her2xcd3 bispecific antibodies for the treatment of her2-positive cancers
|